Muscarinic M1 agonists in the treatment of Alzheimer's disease

被引：30
作者：
Korczyn, AD [1 ]
机构：
[1] Tel Aviv Univ, Sackler Sch Med, Sieratzki Chair Neurol, IL-69978 Ramat Aviv, Israel
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2000年 / 9卷 / 10期
关键词：
Alzheimer's disease; cholinesterase inhibitors; cholinomimetics; muscarinic agonists; therapy;
D O I：
10.1517/13543784.9.10.2259
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The treatment of Alzheimer's disease attempts to correct cholinergic deficiency in the brain. In addition to the established, but restricted, efficacy of acetylcholinesterase inhibitors, attempts are being made to develop agents which will stimulate muscarinic receptors directly. This approach is logical and was found efficacious in several animal models of the disease; however none of these agents succeeded in clinical studies. Several reasons might account for this failure, which are discussed, as well as the prospects for the future.
引用
收藏
页码：2259 / 2267
页数：9
相关论文
共 45 条
  • [1] Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease
    Bodick, NC
    Offen, WW
    Levey, AI
    Cutler, NR
    Gauthier, SG
    Satlin, A
    Shannon, HE
    Tollefson, GD
    Rasmussen, K
    Bymaster, FP
    Hurley, DJ
    Potter, WZ
    Paul, SM
    [J]. ARCHIVES OF NEUROLOGY, 1997, 54 (04) : 465 - 473
  • [2] BODICK NC, 1997, ALZ DIS ASSOC DIS, V4, pS16
  • [3] IN-VIVO CHARACTERIZATION OF MUSCARINIC RECEPTOR SUBTYPES THAT MEDIATE VASODILATATION IN PATIENTS WITH ESSENTIAL-HYPERTENSION
    BRUNING, TA
    CHANG, PC
    HENDRIKS, MGC
    VERMEIJ, P
    PFAFFENDORF, M
    VANZWIETEN, PA
    [J]. HYPERTENSION, 1995, 26 (01) : 70 - 77
  • [4] Bymaster FP, 1997, DRUG DEVELOP RES, V40, P158, DOI 10.1002/(SICI)1098-2299(199702)40:2<158::AID-DDR6>3.3.CO
  • [5] 2-6
  • [6] CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V3458, P319
  • [7] PHYSOSTIGMINE AND ARECOLINE - EFFECTS OF INTRAVENOUS INFUSIONS IN ALZHEIMER PRESENILE-DEMENTIA
    CHRISTIE, JE
    SHERING, A
    FERGUSON, J
    GLEN, AIM
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 1981, 138 (JAN) : 46 - 50
  • [8] Effects of the M1 agonist xanomeline on processing of human β-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells
    DeLapp, N
    Wu, S
    Belagaje, R
    Johnstone, E
    Little, S
    Shannon, H
    Bymaster, F
    Calligaro, D
    Mitch, C
    Whitesitt, C
    Ward, J
    Sheardown, M
    Fink-Jensen, A
    Jeppesen, L
    Thomsen, C
    Sauerberg, P
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 244 (01) : 156 - 160
  • [9] Eglen RM, 1997, DRUG NEWS PERSPECT, V10, P462
  • [10] Alzheimer disease -: Mouse models pave the way for therapeutic opportunities
    Emilien, G
    Maloteaux, JM
    Beyreuther, K
    Masters, CL
    [J]. ARCHIVES OF NEUROLOGY, 2000, 57 (02) : 176 - 181
12345